RT Journal Article
SR Electronic
A1 Vinall, Maria
T1 Bevacizumab Monotherapy Improves DFI in Melanoma Patients at High Risk of Recurrence
JF MD Conference Express
YR 2013
FD SAGE Publications
VO 13
IS 6
SP 16
OP 16
DO 10.1177/155989771306010
UL http://mdc.sagepub.com/content/13/6/16.abstract
AB Results of the preplanned interim analysis of the Adjuvant Avastin Trial in High-Risk Melanoma trial [AVAST-M; ISRCTN81261306; EudraCT 2006-005505-64; Corrie P et al. J Clin Oncol 2013 (suppl; abstr LBA9000)] of melanoma patients at high risk of recurrence has shown that adjuvant bevacizumab (BEV) monotherapy is well tolerated and improved disease-free interval. Longer follow-up is required to determine an impact on the primary endpoint of 5-year overall survival.